Background: Insulin-like growth factor 1 (IGF-1) stimulates PTP␣ tyrosine phosphorylation to enhance cell migration. Results: The scaffold protein RACK1 binds PTP␣ and the IGF-1 receptor, enabling IGF-1-stimulated phosphorylation of PTP␣ by Abl and other kinases. Conclusion: RACK1 coordinates PTP␣ within a signaling complex to mediate PTP␣ phosphorylation. Significance: RACK1 may link PTP␣ to diverse upstream signals that regulate PTP␣ tyrosine phosphorylation-dependent cell motility. 5 The abbreviations used are: PTP, protein tyrosine phosphatase; FAK, focal adhesion kinase; IGF, insulin-like growth factor; SFK, Src family kinase; MEF, mouse embryonic fibroblast.
Protein tyrosine phosphatase ␣ (PTP␣) promotes integrinstimulated cell migration in part through the role of Src-phosphorylated PTP␣-Tyr(P)-789 in recruiting and localizing p130Cas to focal adhesions. The growth factor IGF-1 also stimulates PTP␣-Tyr-789 phosphorylation to positively regulate cell movement. This is in contrast to integrin-induced PTP␣ phosphorylation, that induced by IGF-1 can occur in cells lacking Src family kinases (SFKs), indicating that an unknown kinase distinct from SFKs can target PTP␣. We show that this IGF-1stimulated tyrosine kinase is Abl. We found that PTP␣ binds to the scaffold protein RACK1 and that RACK1 coordinates the IGF-1 receptor, PTP␣, and Abl in a complex to enable IGF-1stimulated and Abl-dependent PTP␣-Tyr-789 phosphorylation. In cells expressing SFKs, IGF-1-stimulated phosphorylation of PTP␣ is mediated by RACK1 but is Abl-independent. Furthermore, expressing the SFKs Src and Fyn in SFK-deficient cells switches IGF-1-induced PTP␣ phosphorylation to occur in an Abl-independent manner, suggesting that SFK activity dominantly regulates IGF-1/IGF-1 receptor signaling to PTP␣. RACK1 is a molecular scaffold that integrates growth factor and integrin signaling, and our identification of PTP␣ as a RACK1 binding protein suggests that RACK1 may coordinate PTP␣-Tyr-789 phosphorylation in these signaling networks to promote cell migration.
Migration is a fundamental cell process that is regulated by the cellular environment. Soluble growth factors that bind to receptor protein tyrosine kinases and extracellular matrix components that engage receptor integrins are important stimuli of cell movement. Growth factor-and extracellular matrix-induced migration signaling are often integrated at multiple levels, and both are regulated by reversible tyrosine phosphorylation.
Receptor-like protein-tyrosine phosphatase ␣ (PTP␣) 5 plays important roles in integrin-stimulated cell migration, where it not only regulates, but is regulated by, tyrosine phosphorylation. Upon integrin engagement, PTP␣ acts catalytically to dephosphorylate and activate Src, enabling the ensuing Srcmediated activation of focal adhesion kinase (FAK) and formation of the central Src-FAK kinase complex (1) (2) (3) . PTP␣ itself is a target of activated Src-FAK and is phosphorylated at a tyrosine site in its C-terminal tail, Tyr-789 (4) . A role for PTP␣-Tyr(P)-789 in signaling events that promote cell migration is evident from studies of cells expressing a mutant PTP␣ (Y789F) that, although catalytically active, cannot be phosphorylated at Tyr-789. In these cells, Src is activated upon integrin engagement, but defective cytoskeletal remodeling and focal adhesion formation result in impaired cell movement (4) .
PTP␣-Tyr(P)-789 is enriched in focal adhesions (5) , indicating that its signaling is localized in these integrin-tethered multiprotein complexes. We have found that it regulates the localization of the scaffolding protein p130Cas (Cas) to the adhesion sites, thereby promoting Src-Cas interaction and Src-mediated Cas tyrosine phosphorylation, which activates migration effectors such as Rac1 and p21-activated kinase (6) . The mechanism of PTP␣-mediated Cas recruitment to adhesions involves the recognition of Tyr(P)-789 by the SH2 domain of the Cas-binding protein BCAR3 and formation of a PTP␣-(Tyr(P)-789)⅐BCAR3-Cas complex (6) . Therefore, in addition to its early catalytic role as an Src activator, PTP␣ also plays a non-catalytic role in integrin-stimulated signaling and cell migration that is dependent upon its phosphorylation.
The IGF-1/IGF-1R cell signaling network regulates numerous cell processes, including proliferation, survival, differentiation, and migration. It also regulates multiple malignant cell phenotypes, including invasion and metastasis (7, 8) . IGF-1/IGF-1R induces the phosphorylation of PTP␣ at Tyr-789 (9), revealing PTP␣ as a new target of IGF-1R signaling. The significantly impaired migration response to IGF-1 of fibroblasts expressing mutant Y789F-PTP␣ suggests that PTP␣ phosphorylation at this site is essential for PTP␣-dependent, IGF-1-regulated cell motility (9) . Interestingly, IGF-1/IGF-1R-induced phosphorylation of PTP␣ appears most robust in SYF fibroblasts that lack the Src family kinases (SFKs) Src, Yes, and Fyn, indicating that, in contrast to integrin signaling, this is SFK-independent.
Because the SFKs are the only PTP␣-Tyr-789 kinases known to date, in this study we aimed to identify the non-SFK tyrosine kinase that phosphorylates PTP␣ in response to IGF-1. We report that, in SYF cells, IGF-1-stimulated PTP␣-Tyr-789 phosphorylation is dependent upon activity of the tyrosine kinase Abl. Furthermore, Abl-dependent PTP␣ phosphorylation is mediated through its interaction with RACK1, a molecular scaffold that binds and coordinates IGF-1R, Abl, and PTP␣. The expression of SFKs in SYF cells switches IGF-1stimulated PTP␣-Tyr-789 phosphorylation from Abl-dependent to Abl-independent, resembling that in other SFKexpressing cell types, including several tumor cell lines. Therefore, Abl may be an alternate or "default" PTP␣ kinase in cells lacking active SFKs, possibly reflecting the importance of PTP␣ phosphorylation. The identification of RACK1 as a PTP␣-interacting protein, together with the known ability of RACK1 to bind several integrin signaling proteins and regulate focal adhesion formation (10 -13) , suggests that it may serve as a platform to orchestrate signaling by integrins and by growth factors such as IGF-1 to PTP␣ to promote cell motility.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents-PTP␣ and PTP␣-Tyr(P)-789 antibodies have been described previously (4) . Antibodies to Crk, FAK, RACK1, and Grb2 were from BD Transduction Laboratories. Anti-IGF-1R and c-Abl antibodies were from Sigma-Aldrich. Antibodies to Akt-Ser(P)-473, Akt, p44/42 MAPK-Thr(P)-202/Tyr(P)-204, IGF-1R-Tyr(P)-1131, Abl-Tyr(P)-245, and CrkL-Tyr(P)-207 were from Cell Signaling Technology. Anti-Tyr(P) (4G10) antibody was from Upstate Biotechnology. Antibody to FAK-Tyr(P)-397 was from Invitrogen. Human recombinant IGF-1 was from Sigma-Aldrich. Imatinib and nilotinib were obtained from LC Laboratories, and PF-573228 was from Selleckchem.
Cell Culture and Treatments-SYF cells and MEFs were cultured in DMEM. MCF-7, IMR-32, TC-32, and BV173 were cultured in RPMI medium. All culture media were supplemented with 10% FBS. Prior to 10-min treatment with IGF-1, cells were starved in medium without serum overnight. In some experiments, serum-starved cells were pretreated with rapamycin for 2 h, nilotinib or imatinib for 3 h, or PF-573228 for 1 h prior to IGF-1 stimulation. siRNAs, Plasmids, and Transfection-Control non-targeting siRNA and siRNAs targeting mouse or human RACK1 (ON-TARGETplus SMARTpool, Gnb2l1), and mouse c-Abl (ON-TARGETplus SMARTpool, mouse Abl1) were from Dharmacon. Cells were transfected with 20 nM mouse siRNA or 50 -100 nM human siRNA using Lipofectamine RNAiMax reagent (Invitrogen) and grown for 48 h before further experimentation. Cells growing in a 6-cm culture dish were transfected with 2.5 g of pXJ41neo-Src or pXJ41neo-Fyn (42) using Lipofectamine LTX (Invitrogen) and cultured for 24 h before further experimentation.
Cell Lysis, Immunoprecipitation, and Immunoblot Analysis-Cells were harvested in lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM Na 3 VO 4 , 1 mM PMSF, 10 g/ml leupeptin, and 10 g/ml aprotinin). Cell lysates were incubated on ice for 30 min and then centrifuged at 13,000 rpm for 15 min. The resulting supernatants were collected and assayed for protein concentration using Bio-Rad reagent prior to immunoblotting experiments. For immunoprecipitation experiments, cells were lysed in the above buffer lacking sodium deoxycholate and SDS.
In Vitro Kinase Assay-Abl immunoprecipitates were incubated with 10 g of recombinant Crk (Millipore) and 100 M ATP in a total volume of 40 l of kinase buffer (20 mM HEPES (pH 7.0), 150 mM NaCl, 1% Triton X-100, 200 M Na 3 VO 4 , 10% glycerol, 1 mM MgCl 2 , 2 mM MnCl 2 , 1 mM PMSF, 2 mM DTT, and 10 g/ml aprotinin) for 30 min at 37°C. The reactions were stopped with Laemmli sample buffer, and the supernatant was subjected to immunoblotting with anti-Tyr(P) (4G10) antibody to detect tyrosine-phosphorylated Crk.
PTP␣-D1 Scanning Peptide Array-A scanning peptide array of 15-mer peptides covering the sequence of PTP␣ amino acids 219 -468 (in the D1 catalytic domain), with a sequential twoamino acid shift (all E-O series peptides) or three-amino acid shift (all B-D and P series peptides) at the amino terminus of each peptide, was synthesized on a cellulose membrane support by automatic SPOT synthesis (14) using the AutoSpot peptide synthesizer (Intavis AG Bioanalytical Instruments). The membrane was incubated with 10 g/ml recombinant GST-RACK1. After washing, the membrane was probed with antibody to RACK1, followed by a secondary antibody coupled to horseradish peroxidase and enhanced chemiluminescence detection.
RESULTS
Abl Is Required for IGF-1-stimulated Tyrosine Phosphorylation of PTP␣ in SYF Fibroblasts-IGF-1 induces the robust phosphorylation of PTP␣ at Tyr-789 in SYF fibroblasts that lack the Src family kinase members Src, Yes, and Fyn, and this is independent of IGF-1-induced PI3K and MAPK signaling (9) .
To determine the identity of the tyrosine kinase that regulates PTP␣ phosphorylation in response to IGF-1 stimulation, we investigated other IGF-1-mediated adhesion signaling pathways in SYF cells. The mammalian target of rapamycin inhibitor rapamycin inhibits the IGF-1-stimulated S6K1-mediated tyrosine phosphorylation of the focal adhesion proteins FAK, p130Cas, and paxillin and reduces cell motility (15) . We found that rapamycin treatment of SYF fibroblasts inhibits basal and IGF-1-stimulated S6 phosphorylation but has no effect on PTP␣-Tyr-789 phosphorylation (Fig. 1A) . Another link between IGF-1 and adhesion signaling is mediated by the tyrosine kinase Abl (16, 17) . We tested whether the Abl inhibitors imatinib (STI571) and nilotinib blocked IGF-1-stimulated phosphorylation of PTP␣. Both compounds were effective inhibitors because PTP␣-Tyr-789 phosphorylation is blocked by 10 M imatinib or 2.5 M nilotinib ( Fig. 1B) , identifying Abl as a candidate PTP␣ kinase.
To confirm the requirement for Abl in IGF-1 signaling to PTP␣, Abl expression was silenced in SYF cells using Abl-targeted siRNA. This eliminated the IGF-1-stimulated phosphorylation of PTP␣ while not affecting expression of the Ablrelated kinase Arg (Fig. 1C ). Treating the cells with control non-targeting siRNA had little, if any, effect on Abl expression and did not affect IGF-1-stimulated phosphorylation of PTP␣ (Fig. 1C ). We further examined whether Abl was activated upon IGF-1 stimulation of SYF cells. Abl immunoprecipitates were prepared from lysates of IGF-1-treated or untreated cells and probed for phosphorylation at Tyr-245, an event that corresponds with Abl activation (18, 19) . A dramatic IGF-1-induced increase in Abl-Tyr(P)-245 was detected that, like PTP␣-Tyr-789 phosphor-ylation, was prevented by nilotinib ( Fig. 1D ). Abl immunoprecipitates were also used in in vitro kinase assays where they were mixed with recombinant Crk, an Abl substrate (20, 21) . Reaction supernatants were resolved by SDS-PAGE and immunoblotted with anti-Tyr(P) antibody, revealing a nilotinib-sensitive, IGF-1-stimulated tyrosine phosphorylation of Crk ( Fig. 1E ). CrkL-Tyr-207 and CrkII-Tyr-221 are Abl-phosphorylated sites (20) , and probing cell lysates with an antibody that recognizes both phosphosites showed that IGF-1 stimulated Crk phosphorylation and that this was inhibited by nilotinib ( Fig. 1F, top panel) . Notably, IGF-1R, Akt, and MAPK phosphorylation/activation were unaltered in response to nilotinib treatment ( Fig. 1F ). Together, our results indicate that IGF-1 activates Abl and that PTP␣-Tyr-789 phosphorylation is dependent on this event.
PTP␣ and Abl Associate in a Complex with the IGF-1R and RACK1 in SYF Fibroblasts-Because our findings suggest that IGF-1-induced phosphorylation of PTP␣ is dependent on Abl, we investigated whether this kinase and phosphatase interact in prior to the addition of IGF-1 (100 ng/ml) for 10 min as indicated. Lysates were probed for Tyr(P)-789-PTP␣ and PTP␣ and, in A, for phospho-S6 (pS6). C, cells were transfected with non-targeting (si-cont) or Abl-specific (si-Abl) siRNAs or mock-transfected (none) and then serum-starved and treated with or without IGF-1 for 10 min. Lysates were probed for Abl, Tyr(P)-789-PTP␣, and PTP␣ (first, second, and third panels), and lysates from other experiments were probed for Abl and Arg ( fourth and fifth panels). D, serum-starved cells were treated with or without 2.5 M nilotinib for 3 h and then treated with or without IGF-1. Abl immunoprecipitates (IP) were probed for Tyr(P)-245-Abl and Abl. E, as in D, except that Abl immunoprecipitates were used in in vitro kinase (IVK) assays with recombinant Crk as substrate. Stopped reactions were centrifuged, and the supernatants were probed for Tyr(P) (top panel). The detected signal migrated at the expected position of Crk (arrow). Reaction pellets were probed for Abl (bottom panel). F, lysates of cells treated as in D were probed with the indicated antibodies. SYF fibroblasts. Indeed, PTP␣ was detected in Abl immunoprecipitates, and Abl was present in PTP␣ immunoprecipitates (Fig. 2, A and B) . IGF-1 increased the association, whereas nilotinib abolished it (Fig. 2, A and B) , suggesting that the interaction of Abl with PTP␣ is enhanced upon IGF-1-induced Abl activation and is dependent upon Abl activity.
We found previously that PTP␣ and the IGF-1R␤ associate with one another independently of IGF-1 treatment (9) . Others have reported that the IGF-1R binds to the scaffolding protein RACK1 and, in response to IGF-1, regulates the association of various proteins with RACK1 (11, 13) . Furthermore, in response to IGF-1, Abl is activated and catalyzes the phosphorylation of RACK1 that enhances or stabilizes the association of FAK with RACK1 (17) . In view of these findings and the ability of RACK1 to bind to multiple proteins, we investigated whether the PTP␣-IGF-1R interaction and the PTP␣-Abl interaction are coordinated by RACK1. Immunoprecipitates of RACK1 contained PTP␣, IGF-1R␤, and Abl (Fig. 2, C and D) . The interaction of PTP␣ and IGF-1R␤ with RACK1 was not affected by IGF-1 treatment or by nilotinib. However, IGF-1 stimulation consistently increased the amount of Abl associated with RACK1 (1.54-Ϯ 0.18-fold over that in the absence of IGF-1, p Ͻ 0.01, n ϭ 4), and nilotinib virtually eliminated the Abl-RACK1 interaction (Fig. 2D ). Together, these data indicate that IGF-1R, Abl, and PTP␣ interact in a complex that is coordinated by RACK1 and that IGF-1-induced activation of Abl enhances its association with the complex.
RACK1 Is Essential for IGF-1-stimulated Phosphorylation of PTP␣ and for the Interaction of PTP␣ and Abl in SYF Fibroblasts-Because RACK1 functions as a central scaffold that physically complexes IGF-1R, Abl, and PTP␣, RACK1 may also be essential for the functional interactions between these proteins. We therefore investigated whether IGF-1-stimulated phosphorylation of PTP␣-Tyr-789 was dependent on RACK1.
The siRNA-mediated silencing of RACK1 abolished PTP␣ phosphorylation, whereas control non-targeting siRNA treatment had no effect (Fig. 3A) . To determine whether RACK1 is enabling IGF-1R/Abl-mediated PTP␣ phosphorylation by bringing PTP␣ into proximity with IGF-1R and Abl, we tested the effect of silencing RACK1 expression upon formation of the protein complex. PTP␣ immunoprecipitates prepared from RACK1-depleted SYF cells that were stimulated with or without IGF-1 did not contain detectable IGF-1R␤ or Abl, in contrast to PTP␣ immunoprecipitates from cells treated with control nonspecific siRNA (Fig. 3B ). Efficient RACK1 silencing was confirmed by probing the cell lysates for RACK1 ( Fig. 3B , bottom panel).
FAK Activity Is Not Required for IGF-1-stimulated Tyrosine Phosphorylation of PTP␣ in SYF Fibroblasts-Integrin signaling enhances PTP␣ phosphorylation at Tyr-789 in a FAK-dependent manner (4). In addition, FAK, in association with RACK1, modulates cell migration in response to IGF-1 (17) . Therefore, we asked whether FAK is important for PTP␣-Tyr-789 phosphorylation in response to IGF-1. Our coimmunoprecipitation results demonstrate that FAK is a component of the PTP␣⅐IGF-1R⅐RACK1 complex. Nilotinib treatment disrupts FAK association with the complex (Fig. 4A) , consistent with the action of Abl in mediating the interaction of FAK with RACK1 (17). Furthermore, IGF-1 treatment induces FAK autophosphorylation at Tyr-397 in SYF cells (Fig. 4B) , indicative of FAK activation. However, treatment with increasing concentrations of the FAK inhibitor PF-573228 (PF-228) (22) showed that 0.1 M PF-228 effectively blocked IGF-1-induced FAK-Tyr-397 phosphorylation without obviously affecting PTP␣-Tyr-789 phosphorylation or IGF-1R, Akt, Crk, and MAPK phosphorylation/activation ( Fig. 4B ). Impairment of IGF-1-induced MAPK activation was detectable at 1 M PF-228, but reduced PTP␣-Tyr-789 phosphorylation was only apparent in cells treated with 10 M PF-228 and occurred concomitantly with reduced phosphorylation of IGF-1R, Akt, and Crk. The latter effects are therefore likely to represent decreased IGF-1R signaling arising from nonspecific inhibitory actions of PF-228 at a higher concentration (22) . These results indicate that, despite the Abl-mediated association of FAK with the RACK1 coordinated protein com- . RACK1 is required for IGF-1-induced PTP␣ tyrosine phosphorylation and for the interaction of PTP␣ with the IGF-1R and Abl. SYF cells were transfected with or without (none) non-targeting (si-cont) or RACK1specific (si-RACK1) siRNAs. The cells were serum-starved and then treated with IGF-1 for 10 min. A, lysates were probed for RACK1, Tyr(P)-789-PTP␣, and PTP␣. B, the cells transfected with non-targeting or RACK1-specific siRNAs were serum-starved and then treated as indicted with 2.5 M nilotinib (Nilot) for 3 h prior to the addition of IGF-1 for 10 min. PTP␣ immunoprecipitates (IP) were probed for IGF-1R␤, Abl, and PTP␣ (first, second, and third panels), and lysates were probed for RACK1 and actin (fourth and fifth panels).
plex, FAK activity is not required for IGF-1-stimulated PTP␣ tyrosine phosphorylation.
Abl Activity Is Not Required for IGF-1-stimulated Phosphorylation of PTP␣ in Other Cell Types-IGF-1 signaling promotes the proliferation, migration, and invasion of a wide variety of tumor cells (7, 8) . PTP␣ has been implicated in various cancers, including colon carcinoma, oral squamous carcinoma, gastric carcinoma, and breast carcinoma (23) (24) (25) (26) (27) . Altering PTP␣ expression has diverse effects on the growth, migration, invasion, and metastasis of various breast and colon cancer cell lines (26 -29) . To investigate whether IGF-1 effects on cancer cells may be mediated via its actions on PTP␣, we determined whether IGF-1 stimulates PTP␣-Tyr-789 phosphorylation in cancer cells. We found that PTP␣ undergoes robust tyrosine phosphorylation in all six tested cancer cell lines in response to IGF-1 stimulation (Fig. 5A ). To establish whether Abl is important for this, we tested the effect of nilotinib on IGF-1-mediated PTP␣-Tyr-789 phosphorylation in three of the cancer cell lines: MCF-7 (breast adenocarcinoma), IMR-32 (neuroblastoma), and TC-32 (Ewing sarcoma). Similar to SYF cells, IGF-1 induced Abl activation, as indicated by enhanced Crk phos- phorylation, which was sensitive to nilotinib inhibition (Fig.  5B ). However, nilotinib treatment did not inhibit PTP␣-Tyr-789 phosphorylation in any of the cancer cells (Fig. 5B) , distinct from its effect on PTP␣ in SYF cells.
Human chronic myeloid leukemia arises from a chromosomal abnormality leading to the expression of the Bcr-Abl fusion protein, a constitutively active form of Abl. The Abl inhibitors imatinib and nilotinib are widely used to treat chronic myeloid leukemia. Therefore, we investigated PTP␣ phosphorylation in the BV173 chronic myeloid leukemia cell line, where Abl is constitutively active. Imatinib or nilotinib treatment completely inhibited Bcr-Abl activity, as evidenced by the abolition of Crk phosphorylation, but did not reduce PTP␣ tyrosine phosphorylation (Fig. 5C ).
We next investigated the Abl dependence of IGF-1-stimulated PTP␣ phosphorylation in fibroblasts that represent a wild-type counterpart to the SFK-deficient SYF cells. Treating MEFs with IGF-1 induced a rapid but small increase (ϳ1.3fold) in PTP␣ tyrosine phosphorylation and enhanced Crk phosphorylation (Fig. 5D) . In contrast to SYF fibroblasts, IGF-1-induced PTP␣ phosphorylation in MEFs was unaffected by nilotinib even though Crk phosphorylation was abolished ( Fig.  5D ), suggesting that the latter, but not the former event, is Abldependent. Similar to SYF cells, nilotinib treatment did not alter IGF-1R, Akt, and MAPK phosphorylation.
Together, the above findings indicate that IGF-1-induced PTP␣ tyrosine phosphorylation is regulated by mechanisms that differ between SYF fibroblasts and other cell types, with nilotinib sensitivity distinguishing the respective Abl-dependent and -independent nature of IGF-1 signaling to PTP␣. Furthermore, the manifestation of this difference between the closely related SYF fibroblasts (SFK-deficient MEFs) and wild-type MEFs suggests that it may be determined by the presence or absence of the SFKs Src, Yes, and Fyn.
Reintroduction of SFKs into SYF Cells Eliminates the Abl Dependence of IGF-1-mediated PTP␣ Tyrosine Phosphorylation-To determine whether restoring SFK expression to SYF cells would alter the requirement for Abl in IGF-1-mediated PTP␣ tyrosine phosphorylation, we introduced Src and Fyn into SYF fibroblasts and confirmed their expression by
Western blotting (Fig. 6A, bottom two panels) . In Src-or Fyntransfected cells, IGF-1 stimulated a smaller increase (ϳ1.5fold) in PTP␣-Tyr-789 phosphorylation compared with the more than 2-fold increase detected in mock-transfected SYF cells (Fig. 6, A and B) . Crk phosphorylation was detectable in unstimulated Src-or Fyn-expressing cells, but IGF-1 did not stimulate this further (Fig. 6, A and C) , suggesting that Abl is active but that its activity is IGF-1-independent. Most interestingly, the presence of Src or Fyn eliminated the nilotinib sensitivity of IGF-1-mediated PTP␣ tyrosine phosphorylation despite Crk phosphorylation remaining susceptible to nilotinib inhibition (Fig. 6, A and B) . Therefore, the expression of Src or Fyn is sufficient to abolish the Abl dependence of IGF-1-induced PTP␣-Tyr-789 phosphorylation.
Despite the altered Abl dependence of IGF-1-induced PTP␣ phosphorylation, wound healing assays demonstrated that IGF-1-induced migration of the parental and the Src/Fyn-expressing SYF cells was inhibited by nilotinib (data not shown). Taken together with the observation that phosphorylation of the Abl substrate and the migration-associated molecule Crk in these three types of cells is abolished by nilotinib ( Fig. 6A ), this indicates that Abl signaling to molecules other than PTP␣, possibly including some of the Abl substrates involved in the regulation of cell shape and motil- ity (30, 31) , is occurring in the Src/Fyn expressing cells and remains critical for migration.
RACK1 Plays a Role in IGF-1-mediated PTP␣ Tyrosine Phosphorylation in MCF-7 Cells-Because RACK1 is essential for IGF-1-stimulated and Abl-mediated PTP␣-Tyr-789 phosphorylation in SYF cells, we investigated whether, as with Abl, there was a different requirement for RACK1 in IGF-1 induced PTP␣ phosphorylation in other cell types. To this end, we used human RACK1-targeted siRNA to deplete RACK1 expression in MCF-7 breast cancer cells. About 70% of the RACK1 was depleted by treatment with 50 nM siRNA, and this was not increased when the siRNA concentration was doubled (Fig. 7A) . Nevertheless, a significant decrease in IGF-1-induced PTP␣ tyrosine phosphorylation was detected in RACK1-depleted cells (ϳ1.5-fold versus 2.5-fold in control cells, respectively) ( Fig. 7, A  and B) . This suggests that RACK1 is important for IGF-1-induced PTP␣ phosphorylation regardless of the presence or absence of SFKs.
PTP␣ Interacts Directly with RACK1-To investigate the interaction of PTP␣ and RACK1 in more detail, we first determined whether recombinant GST-PTP␣ fusion proteins (depicted schematically in Fig. 8A ) could pull down RACK1 from SYF cell lysate. RACK1 was not pulled down by GST alone, but RACK1 associated with GST-PTP␣ proteins containing both or either of the homologous D1 membrane-proximal and D2 membrane-distal catalytic domains (Fig. 8B) . To further refine the RACK1 binding region, we tested two forms of D1-truncated GST-PTP␣ in pulldown assays. PTP␣-D1 lacking some carboxyl-terminal sequence (D1-442) was still able to pull down RACK1, whereas the deletion of most of the D1 catalytic domain (D1-260) completely abolished RACK1 binding (Fig. 8C) , indicating that PTP␣ amino acids 261-442 contained a RACK1 binding site. We also found that a catalytically inactive mutant form of PTP␣ (D1sD2s) in which the catalytic cysteine residue in both D1 and D2 was mutated to a serine residue (C433S/C723S) was able to bind RACK1 (Fig. 8C) .
To identify the RACK1 binding sequence within PTP␣-D1, we constructed a scanning peptide array corresponding to the PTP␣-D1 sequence. The array contains a series of 15-mer overlapping peptides with a two-or three-amino acid shift between neighboring peptides that covers the PTP␣ sequence from amino acids 219 -468. This was probed with recombinant GST-RACK1, and peptide spots that bound to GST-RACK1 were visualized by probing with antibody to GST. Two series of peptide spots bound to GST-RACK1: C4 -7/D1 and D7/E1-2 ( Fig. 8D ). Common amino acids within each overlapping peptide series defined the two sequences recognized by RACK1 as PTP␣ amino acids 261-263 (RYV) and 284 -293 (SDYINAS-FIN) (Fig. 8D) , with peptides containing the former sequence exhibiting the stronger interaction. Both of these sequences are located in the minimal RACK1-interacting region of D1 defined in the GST pulldown assays. These results indicate that PTP␣ and RACK1 can interact directly. The ability of RACK1 to bind to the non-identical but homologous sequences in the corresponding regions of PTP␣-D2, 554-RVL-556 and 577-TDYV-NASFID-586, remains to be determined.
DISCUSSION
Our study to elucidate the mechanism of IGF-1-stimulated PTP␣-Tyr-789 phosphorylation in SYF cells has identified Abl as a novel kinase that can phosphorylate PTP␣. Moreover, we report that PTP␣ interacts with RACK1 and is a component of a RACK1-scaffolded protein complex that coordinates IGF-1-regulated signaling to PTP␣ by bringing IGF-1R, Abl, and PTP␣ into proximity to promote Abl-catalyzed PTP␣ phosphorylation. In the RACK1-coordinated signaling complex that we characterized in SYF cells, the transmembrane molecules IGF-1R␤ and PTP␣ are constitutively associated with RACK1 in a manner unaltered by the presence or absence of the growth factor IGF-1 or by the activity status of Abl. On the other hand, Abl association with the complex is enhanced by IGF-1 concomitant with its IGF-1-induced activation and is abolished by nilotinib inhibition, suggesting that Abl binding to RACK1 requires the active conformation of the kinase. A third tyrosine kinase in the RACK1 complex, FAK, mimics Abl in the conditions of its association with RACK1. This is consistent with a study showing that FAK binding to Tyr-52 of RACK1 is regulated by the phosphorylation of this site by Abl and, therefore, is Abl-dependent (17) . Disruption of the complex prevents IGF-1-induced PTP␣ phosphorylation, as occurs upon the depletion of RACK1 that abrogates the physical interaction of PTP␣ with IGF-1R␤ and Abl and upon the depletion of Abl or nilotinibmediated Abl inhibition that disrupts the interaction of Abl with RACK1. In addition to enabling Abl interaction with RACK1, our experiments with the kinase inhibitors nilotinib and PF-228 indicate that Abl catalytic activity, rather than that of IGF-1R␤ or FAK, is responsible for catalyzing PTP␣-Tyr-789 phosphorylation. Unlike Abl, the activation of IGF-1R and its association with RACK1 as well as its signaling to downstream molecules like Akt and MAPK are not affected by nilotinib, indicating that PTP␣-Tyr-789 phosphorylation is not directly catalyzed by IGF-1R␤. Although FAK association with RACK1 is nilotinib-sensitive, FAK activity is clearly not required for PTP␣ phosphorylation because these can be distinguished by concentration-dependent treatment with the FAK inhibitor PF-228. In contrast to SYF fibroblasts, we found that IGF-1-stimulated PTP␣-Tyr-789 phosphorylation in other cell types, such as wild-type MEFs and various tumor cells, is Abl-independent. This was surprising because IGF-1 activates Abl in these cells, as indicated by the IGF-1-induced and nilotinib-sensitive phosphorylation of the Abl substrate Crk and as reported by others (17, 32) . Interestingly, restoring SFK expression to SYF cells rendered IGF-1-induced PTP␣ phosphorylation Abl-independent. This switch indicates that the presence of Src or Fyn prevents Abl from phosphorylating PTP␣ and provides a possible explanation for the Abl independence of this reaction in normal MEFs and the tumor cell lines. In SFK-expressing SYF cells, phosphorylation of the Abl substrate Crk remained sensitive to inhibition by nilotinib, demonstrating that Src or Fyn expression does not globally inhibit Abl. However, although PTP␣ phosphorylation was still up-regulated by IGF-1, Abl activity was released from regulation by IGF-1, suggesting that the presence of SFKs may interfere with the presence or ability of Abl to function within the RACK1-scaffolded IGF-1R⅐PTP␣ signaling complex. Although Src and Fyn are RACK1 binding proteins (33, 34) , this effect is unlikely to involve competitive displacement of Abl from RACK1 because the interaction of at least Src with Tyr-228 and/or Tyr-246 in the RACK1 WD6 repeat is distinct from the Abl binding region in the WD1-3 repeats of RACK1 (17, 35) . In support of SFKs not affecting the interaction of the substrate PTP␣ in the complex, IGF-1-induced PTP␣ phosphorylation in MCF-7 cells that express SFKs was also RACK1-dependent. Therefore, the RACK1-PTP␣ interaction is important for PTP␣-Tyr-789 phosphorylation in SFK-expressing as well as SFK-deficient cells.
RACK1 belongs to the WD repeat protein family. It can bind many proteins to regulate their localization, interaction, activation, and/or stability and functions as a hub that coordinates and integrates multiple inputs (36 -38) . RACK1 can regulate reversible phosphorylation in cell signaling through its interactions with protein kinases, phosphatases, and their substrates. We have identified PTP␣ as a new RACK1-interacting protein and a role of PTP␣ as a kinase substrate in a RACK1-scaffolded complex. Analysis of a peptide array spanning the sequence of the PTP␣-D1 membrane-proximal catalytic domain pinpoints amino acids 261-263 (RYV) and 284 -293 (SDYINASFIN) in PTP␣ as RACK1 binding sites. The RYV sequence lies at the top of the PTP catalytic cleft, and the central tyrosine is critical for orienting the phosphotyrosine moiety of PTP substrates for dephosphorylation (39) . This raises the possibility that RACK1 binding could occlude substrate binding and prevent PTP␣-D1-catalyzed protein dephosphorylation, representing a mechanism to negatively regulate PTP␣ activity. This would not preclude the non-catalytic role of phosphorylated PTP␣ in promoting cell motility. However, the precise site(s) in PTP␣ that mediate RACK1 binding in vivo remain to be defined, especially because GST-PTP␣ pulldown experiments indicate that both the D1 membrane-proximal and the homologous D2 membrane-distal catalytic domains of PTP␣ can interact with RACK1. Another receptor PTP, PTP, also undergoes a catalytic domain-mediated interaction with RACK1 (40). This and our study suggest that the highly conserved catalytic domains of classical tyrosine-specific members of the PTP family, perhaps especially those of the very closely related receptor PTPs, are capable of interaction with RACK1. These PTPs may represent important components of RACK1-coordinated protein tyrosine phosphorylation signaling.
In summary, we identified RACK1 as a novel binding partner of PTP␣ that couples PTP␣ to the IGF-1R. In the absence of SFKs, RACK1 coordinates IGF-1-stimulated Abl-dependent phosphorylation of PTP␣-Tyr-789. The presence of SFKs switches the mode of IGF-1-induced PTP␣ phosphorylation to one that is Abl-independent and probably catalyzed by SFKs. RACK1 is gaining growing recognition as a scaffolding mediator of migration signaling, including a role in integrating signals that regulate IGF-1 and integrin-stimulated migration (37, 41) . PTP␣-Tyr-789 phosphorylation in response to either IGF-1 or integrin promotes cell migration (4, 9) , and RACK1-regulated PTP␣-Tyr-789 phosphorylation may be a shared functional component of these networks.
